|
|
|
Amarillo Bioscience Partner CytoPharm Approved to Enroll 165 Patient Phase 2 Hepatitis C Trial in Taiwan |
 |
 |
 |
|
Friday, 13 February 2009 00:00 |
|
Amarillo, Texas, February 13, 2009 — Amarillo Biosciences, Inc.(OTCBB: AMAR) today announced that the Taiwanese Department of Health has approved an application to test Amarillo Biosciences’ low dose oral interferon in a Phase 2 hepatitis C clinical trial. CytoPharm, the Company’s partner in Taiwan, will fund and conduct a clinical trial of 165 chronic hepatitis C patients in Taiwan. The patients will receive one of two different dosages of oral human interferon alpha or placebo.
|
|
Last Updated on Monday, 05 April 2010 13:30 |
|
Read more... [Amarillo Bioscience Partner CytoPharm Approved to Enroll 165 Patient Phase 2 Hepatitis C Trial in Taiwan]
|
|
Amarillo Biosciences Issues Progress Report |
|
|
|
|
Monday, 26 January 2009 00:00 |
|
Amarillo, Texas, January 26, 2009 — Amarillo Biosciences, Inc.(ABI) (OTCBB: AMAR) today issued the following Progress Report to shareholders:
|
|
Last Updated on Monday, 05 April 2010 13:31 |
|
Read more... [Amarillo Biosciences Issues Progress Report]
|
|
|
Amarillo Biosciences Agrees to Relocate Company to Junction City Kansas |
|
|
|
|
Wednesday, 14 January 2009 00:00 |
|
State and City Incentives Could Reach $5 Million Over Time
Amarillo, Texas, January 14, 2009 — Amarillo Biosciences, Inc. (AMAR) (OTCBB: AMAR), today announced that the Board of Directors has agreed to accept a relocation package of financial incentives from Junction City, Kansas and the State of Kansas. The proposed city and state incentives are in the form of a stock purchase, loans, grants, research vouchers, low rent, tax relief and training funds. Under the terms of the Agreement, Amarillo Biosciences will move all operations to Kansas before the end of the second quarter of 2009. Junction City is expected to nominate a member to the AMAR Board of Directors.
|
|
Last Updated on Monday, 05 April 2010 13:31 |
|
Read more... [Amarillo Biosciences Agrees to Relocate Company to Junction City Kansas]
|
|
Amarillo Biosciences to Support Western Australian Human Influenza Clinical Trial |
|
|
|
|
Friday, 01 August 2008 01:38 |
|
Amarillo, Texas, August 1, 2008 — Amarillo Biosciences, Inc. (OTCBB: AMAR) today announced that it has agreed to provide interferon lozenges and other support for Western Australia’s’ government (Department of Health) sponsored human influenza clinical trial led by Dr. Manfred Beilharz, Microbiology and Immunology, School of Biomedical, Bimolecular and Chemical Sciences, Faculty of Life and Physical Sciences, The University of Western Australia.
|
|
Last Updated on Thursday, 02 April 2009 12:52 |
|
Read more... [Amarillo Biosciences to Support Western Australian Human Influenza Clinical Trial]
|
|
|
|
|
<< Start < Prev 1 2 3 Next > End >>
|
|
Page 1 of 3 |